StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.15 | $2.12 | -1.40% | 0.1M |
| 05-19 | $2.13 | $2.11 | -0.94% | 0.0M |
| 05-20 | $2.11 | $2.17 | +2.84% | 0.0M |
| 05-21 | $2.14 | $2.22 | +3.74% | 0.0M |
| 05-22 | $2.21 | $2.35 | +6.33% | 0.1M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Annual 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $16.89M | $10.23M |
Operating Income | $-25.92M | $-18.37M | $-36.17M | $-26.83M |
Net Income | $-24.18M | $-16.85M | $-37.80M | $-29.27M |
EPS (Diluted) | $-1.65 | $-1.15 | $-2.80 | $-2.23 |
Total Assets | $27.33M | $32.67M | $60.42M | $64.63M |
Total Liabilities | $11.99M | $11.62M | $28.10M | $27.01M |
Cash & Equivalents | $15.01M | $20.02M | $24.92M | $29.15M |
Free Cash Flow OCF − CapEx | $-24.55M | $-19.07M | $-21.84M | $-17.41M |
Shares Outstanding | 14.65M | 146.58M | 14.64M | 146.38M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.